A comparative study of the efficacy and tolerability of parenteral ceftriaxone and cefotaxime in pediatric population for acute bacillary dysentery in a tertiary care hospital

Authors

  • Sagar K. Department of Pharmacology, Dr. B. R. Ambedkar Medical College, Bangalore, Karnataka, India
  • Shanmukananda P. Department of Pharmacology, Dr. B. R. Ambedkar Medical College, Bangalore, Karnataka, India
  • Veena D. R. Department of Pharmacology, Dr. B. R. Ambedkar Medical College, Bangalore, Karnataka, India
  • Shwetha H. Department of Pharmacology, Dr. B. R. Ambedkar Medical College, Bangalore, Karnataka, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20182090

Keywords:

Acute bacillary dysentery, Cefotaxime, Ceftriaxone, Efficacy, Tolerability

Abstract

Background: Diarrheal disorders in childhood account for a large proportion (18%) of childhood mortality. Among diarrheal diseases, dysentery is a major cause of childhood morbidity and mortality, especially in developing countries.

Methods: This is an open labelled, prospective, randomised, comparative study carried out at Dr. B. R. Ambedkar Medical College Hospital, Bangalore from November 2014 to November 2015 after Institutional Ethics Committee approval. A total of 80 Paediatric patients who met the inclusion criteria were included in the study after taking written informed consent from parents and assigned into two groups, Group A- Inj. Ceftriaxone (50-100mg/kg/day) and Group B- Inj. Cefotaxime (100 mg/kg/day) in divided doses for a period of 3-5 days based on requirement.

Results: In this study, Cefotaxime was non inferior to Ceftriaxone as the Mean Duration of Hospitalisation was 3.30±0.72 days in Group A and 3.30± 0.72 days in Group B with p value of 1.000, showing no statistically significant difference. Both were well tolerated without any reports of ADR (Adverse Drug Reaction).

Conclusions: In this study shows that Inj. Cefotaxime is equally efficacious and well tolerated as Inj. Ceftriaxone in the treatment of Acute Bacillary Dysentery in paediatric patients.

References

Bhutta ZA. Acute Gastroenteritis in Children. Robert M. Kliegman, Richard E. Behrman, Hal B. Jenson, Bonita F. Stanton: Nelson Textbook of Paediatrics: 17th edition: Elsevier Publication, New Delhi, India: Chapter 196 (1191- 93) and Chapter 337(1605- 1618).

Gaeza JM, Cohen MB. Infectious Diarrhea. Robert Wyllie, Jeffrey S. Hyams, Marsha Kay. Paediatric Gastrointestinal and Liver Disease. Elsevier Saunders Publication, 4th Edition, chapter 39; 2006:405-422.

Dutta D, Bhattacharya MK, Dutta S, Datta A, Sarkar D, Bhandari B, et al. Emergence of Multidrug resistant Shigella dysenteriae type 1 Causing Sporadic Outbreak In and Around Kolkata, India. J. Health Popul. Nutr. 2003:21(1):79-80.

Rajeshwari K, Mishra M, Dubey AP, Uppal B, Anuradha S. Spectrum of dysentery in children presenting to a tertiary level teaching hospital in New Delhi. International Journal of Medicine and Medical Sciences. 2013 Apr 30;5(4):158-62.

Camilleri M, Murray JA. Diarrhea and Constipation. Dennis L. Kosper, Anthony S. Fauci, Stephen L. Hauser et al. Harrison’s Principles of Internal Medicine. Mc Graw hill Education publication. 19th Edition, Part 2: Chapter 55; 2015:264-268.

Taneja N. Changing Epidemiology of Shigellosis and Emergence of Ciprofloxacin Resistant Shigellae in India. J. Clin. Microbiol. 2007;45(2):678-9.

Traa BS, Fischer Walker CL, Munos M, Black RE. Antibiotics for the treatment of dysentery in children; Inte J of Epidemio. 2010;39(1):70-4.

Burkhardt JE, Walterspiel JN, Schaad UB. Quinolone Arthropathy in Animals Versus Children: Clinical Infectious Diseases, The University of Chicago. 1997;25:1196-204.

Chalumeau M, Tonnelier S, d’Athis P, Tréluyer JM, Gendrel D, Bréart G, et al. Fluoroquinolone safety in pediatric patients: a prospective, multicenter, comparative cohort study in France. Pediatrics. 2003 Jun 1;111(6):e714-9.

Sendzik J1, Lode H, Stahlmann R. Quinolone-induced arthropathy: an update focusing on new mechanistic and clinical data: International Journal of Antimicrobial Agents. 2009 Mar;33(3):194-200.

Velissariou IM. The use of fluoroquinolones in children: recent advances. Expert review of anti-infective therapy. 2006 Oct 1;4(5):853-60.

Petri WA. Pencillins, Cephalosporins, and other β- Lactam antibiotics. Laurence L. Brunton, BruceA. Chabner, Bjorn C. Knollmann: Goodman and Gilman’s The Pharmacological Basis of Therapeutics: 12th edition: Mc Graw Hill Publication, New York, USA. Chapter 53; 2011:1493-1503.

Rang HP, Dale MM, Ritter JM. Rang and Dale’s Pharmacology: 8th Edition: Elsevier publication, Spain: Chapter 50; 2015:624-628.

Lupoli T, Hooper DC, Arnaout RA, Kahne D, Walker S, Pharmacology of Bacterial and Mycobacterial Infections: Cell Wall Synthesis. Bertram G. Katzung, Anthony J. Trevor. Basic and Clinical Pharmacology. 13th Edition, McGraw Hill Education, Section VIII, Chapter 43; 2015:776-780.

Downloads

Published

2018-05-22

How to Cite

K., S., P., S., D. R., V., & H., S. (2018). A comparative study of the efficacy and tolerability of parenteral ceftriaxone and cefotaxime in pediatric population for acute bacillary dysentery in a tertiary care hospital. International Journal of Basic & Clinical Pharmacology, 7(6), 1109–1113. https://doi.org/10.18203/2319-2003.ijbcp20182090

Issue

Section

Original Research Articles